DocDollars

Actelion Pharmaceuticals, Ltd

CA · United States · Reporting entity ID 100000010476

Total reported 2019–2025
$8.84M
#533 of 2,960 reporting companies — 0% of all reported industry payments
$1.62M in general payments across 1,225 records, plus $7.22M in research funding across 1,496 records.

How it breaks down

General payments $1,616,459
Research funding $7,220,383

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Actelion Pharmaceuticals, Ltd reported $8.84M to US doctors and teaching hospitals from 2019 to 2025, ranking #533 of 2,960 reporting companies. 82% of that was research funding and 18% general payments such as consulting, speaking, food and travel. 1,225 general payment records and 1,496 research records were filed.

Common questions about Actelion Pharmaceuticals, Ltd

How much has Actelion Pharmaceuticals, Ltd paid US doctors?

Actelion Pharmaceuticals, Ltd reported $8,836,842 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $1,616,459 in general payments, $7,220,383 in research funding.

How does Actelion Pharmaceuticals, Ltd rank among drug and device companies?

It ranks #533 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Actelion Pharmaceuticals, Ltd mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.